

Leaders Urge Preparedness for Likely H1N1 Surge

BY HEIDI SPLETE

BETHESDA, MD. — President Obama joined other U.S. government and health leaders at a preparedness summit urging Americans to plan now for a likely surge in cases of the 2009-H1N1 influenza this fall.

“We want to make sure that we are not promoting panic, but we are promoting vigilance and preparation,” President Obama, who was in Italy, said by phone during the summit on July 9 at the National Institutes of Health in Bethesda, Md.

“Our goals are straightforward; to reduce illness and death and minimize so-



‘Our goals are straightforward; to reduce illness and death and minimize social disruption.’

DR. FRIEDEN

cial disruption,” said Dr. Thomas R. Frieden, director of the Centers for Disease Control and Prevention.

Dr. Frieden, along with Kathleen Sebelius, secretary of the Department of Health and Human Services, Janet Napolitano, secretary of the Department of Homeland Security, and Arne Duncan, secretary of the Department of Education, reviewed the status of the government’s efforts to prepare for an anticipated surge in volume of cases of the 2009-H1N1 flu in the fall.

Secretary Sebelius summarized the government’s four-pronged strategy of surveillance, community mitigation, vaccination, and communication. She encouraged all Americans to visit the government’s flu-specific Web site, flu.gov. The site will be updated regularly, and it reinforces ways to prevent spreading the flu, such as following proper handwashing techniques, coughing into your sleeve, and staying home when ill. And in an effort to engage an Internet-savvy population in public health, the site offers visitors to create a 60-second H1N1 video public service announcement. Of all the announcements submitted, one will be chosen by the government for widespread distribution, she said. A \$2,500 prize will go to the maker of the winning video, according to the site.

In addition, Secretary Sebelius outlined the government’s intentions for minimizing the impact of H1N1. The H1N1 vaccine, if it is found to be safe and effective, will be purchased by the federal government, she said, and medical and scientific experts will help prioritize vaccination efforts and “get the shots in the arms of the people who need them most.” A vaccine is currently being evaluated in clinical trials, and safety and effectiveness information should be available this month, she said. If the vaccine is found to be safe and effective, it should be available in limited amounts in Octo-

ber. Based on current evidence, likely high-risk groups that would be the first candidates for the H1N1 vaccine might include younger adults with comorbid conditions, children, and pregnant women.

Federal grants for state health departments to help with preparedness are available, Secretary Sebelius also announced. She added that \$90 million will be available for hospitals to help prepare for the potential surge.

The Department of Homeland Security is focusing on the importance of maintaining essential services if widespread illness contributes to widespread absenteeism, Secretary Napolitano said. She stressed the need to “make sure that plans are in place so the functions of government continue,” and encouraged state and local leaders to host their own local flu preparedness summits.

Because the 2009-H1N1 virus has dis-

proportionately affected children, it is important to “get clear guidance out early,” to schools, said Secretary Duncan. School-closing decisions should be made at the local level, on a school-by-school basis, and only as a last resort, he said.

Secretary Napolitano said that even if the 2009-H1N1 flu is less severe than expected, the procedures being put in place will improve the public health system for future emergencies. ■

First and only
antifungal cream in a pump!
Available in 30g and 90g sizes.

INTRODUCING Fungicidal Power in a Convenient Pump!

*The #1 branded
prescription topical
antifungal cream*
now offers controlled
application in a pump!*

*Targeted power
against Tinea Pedis,
Cruis and Corporis.*



Fungicidal Power You Can Trust®

www.naftin.com

Naftin® (naftifine HCl 1%) Cream is contraindicated in individuals who have shown hypersensitivity to any of its components and is for topical use only. During clinical trials with Naftin® Cream, 1%, the following adverse reactions were reported: burning/stinging, dryness, erythema, itching, local irritation. See brief summary of prescribing information on the following page.

References: 1. IMS NPA Data, March 2009.

© 2009 Merz Pharmaceuticals. All rights reserved.

